Core Insights - ODDITY has experienced a 6.7% increase in shares over the past three months, which is lower than the Zacks Internet-Software industry's 8.5% and the Zacks Computer and Technology sector's 8.4% returns [1] - The company is expanding its business through a strong direct-to-consumer model and personalized products, with brands like IL MAKIAGE and SpoiledChild showing strong double-digit growth [1] Group 1: Business Model and Growth - ODDITY has invested significantly in artificial intelligence, data science, machine learning, and computer vision, enhancing consumer engagement through online advertising [2] - The direct-to-consumer model allows ODDITY to gather direct data insights that are not available through traditional offline channels [2] - ODDITY's reliance on consumer data enables personalized product recommendations, positioning the company as a disruptor in the cosmetics industry [4] Group 2: Market Context - The cosmetics industry is traditionally slow-moving and primarily offline, with major players like Estée Lauder, Ulta Beauty, and Coty relying on physical retail outlets [3] - ODDITY is leveraging its consumer insights to expand sales in the U.S. market, achieving $414.1 million in U.S. sales in 2023, a 71.7% increase from 2022 [7] Group 3: Financial Performance - ODDITY's net revenues reached $508.7 million in 2023, up 56.7% from $324.5 million in 2022, with expectations for 2024 revenues in the range of $642-$644 million [8] - The Zacks Consensus Estimate for 2024 revenues is $643 million, indicating a year-over-year growth of 26.4% [8] Group 4: Future Plans - ODDITY plans to launch two new brands, including a telehealth platform, to further capitalize on the $600 billion global online cosmetics market [7]

Core Insights - Mesoblast Limited has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its stromal cell therapy Revascor® (rexlemestrocel-L) aimed at treating hypoplastic left heart syndrome (HLHS) in children, following positive results from a randomized controlled trial [1][2][3] Group 1: FDA Designations and Implications - The RMAT designation allows Mesoblast to expedite the development of Revascor, providing benefits such as rolling review and eligibility for priority review upon filing a Biologics License Application (BLA) [3] - Earlier in the year, Revascor was also granted Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) by the FDA, indicating the serious nature of HLHS and its rarity [2] Group 2: Clinical Trial Results - A blinded, randomized, placebo-controlled trial involving 19 children with HLHS demonstrated that a single administration of Revascor led to significantly larger increases in left ventricular end-systolic and end-diastolic volumes over 12 months compared to controls, with p-values of 0.009 and 0.020 respectively [4] - These results suggest clinically important growth of the left ventricle, which is crucial for successful surgical correction and reducing the risk of heart failure and other complications [5] Group 3: About HLHS and Revascor - HLHS is a severe congenital heart defect that can lead to high neonatal mortality rates, accounting for 25% to 40% of all neonatal cardiac deaths if not treated promptly [6] - Revascor is an allogeneic therapy derived from immunoselected mesenchymal precursor cells, which may provide multiple benefits including neovascularization and reduction of inflammation [7] Group 4: Company Overview - Mesoblast is a leader in developing allogeneic cellular medicines for severe inflammatory conditions, with a strong intellectual property portfolio extending to at least 2041 [8][9] - The company is also advancing other product candidates for various indications, including remestemcel-L for inflammatory diseases and rexlemestrocel-L for chronic heart failure [10]

Group 1 - The article discusses the initiation of coverage on Oddity Tech Ltd., an Israeli-based consumer tech firm aiming to disrupt the beauty and wellness industry [1] - Oddity Tech Ltd. is listed on NASDAQ under the ticker ODD, indicating its presence in the public market [1] Group 2 - The firm has intriguing ambitions, suggesting a focus on innovation and potential market disruption within its sector [1]

From a technical perspective, Oddity Tech (ODD) is looking like an interesting pick, as it just reached a key level of support. ODD recently overtook the 20-day moving average, and this suggests a short-term bullish trend.A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.Simi ...

Core Viewpoint - Oddity Tech (ODD) has shown a recent price increase and analysts suggest there is potential for further upside based on price targets and earnings estimates [1][9]. Price Targets - The mean price target for ODD is $52.14, indicating a potential upside of 28.7% from the current price of $40.50 [1]. - Price targets from analysts range from a low of $42 to a high of $66, with a standard deviation of $8.49, suggesting variability in estimates [2]. - The lowest estimate indicates a 3.7% increase, while the highest suggests a 63% upside [2]. Analyst Sentiment - Analysts have shown increasing optimism regarding ODD's earnings prospects, with a strong consensus on higher EPS estimates [9]. - Over the last 30 days, three estimates have been revised upward, leading to a 13.1% increase in the Zacks Consensus Estimate [10]. - ODD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [11]. Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][5]. - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [6]. - A low standard deviation in price targets indicates a high degree of agreement among analysts, which can be a starting point for further research [7].

Oddity Tech (ODD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual ...

Core Points - ODDITY Tech Ltd. has announced a transaction to repurchase approximately 2.35 million Class A Ordinary Shares for about $100 million at a price of $42.501 per share, funded from existing cash resources [1][2] - The board of directors believes the repurchase is in the best interest of the company due to its strong balance sheet and current circumstances, and this transaction is separate from the ongoing share buyback plan [2][3] - Following the transaction, L Catterton will own around 4 million shares, equating to approximately 7% of the company's outstanding shares as of September 30, 2024 [3] Financial Position - As of September 30, 2024, ODDITY held $248 million in cash, cash equivalents, and investments, along with an undrawn credit facility of $100 million, and has no financial debt [4] - For the 12 months ending September 30, 2024, the company generated $127 million in free cash flow, with $130 million from operations and $3 million in capital expenditures [5][10] - The company has repurchased a total of $147 million of its shares year-to-date, including $47 million under the standing share buyback plan [3] Business Overview - ODDITY is a consumer tech company focused on building and scaling digital-first brands in the beauty and wellness sectors, serving approximately 50 million users through its AI-driven platform [12] - The company operates with headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston [12]

Oddity Tech Ltd (NASDAQ:ODD) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Maria Lycouris - Investor Relations Oran Holtzman - Co-Founder and Chief Executive Officer Lindsay Drucker Mann - Global Chief Financial Officer Conference Call Participants Dara Mohsenian - Morgan Stanley Nick Cronin - Truist Securities Operator Good morning, and welcome to the ODDITY's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated time for prepa ...

Oddity Tech (ODD) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 45.45%. A quarter ago, it was expected that this online retailer of cosmetics and beauty products would post earnings of $0.67 per share when it actually produced earnings of $0.82, delivering a surprise of 22.39%.Over ...

Exhibit 99.1 ODDITY TECH REPORTS RECORD THIRD QUARTER RESULTS, RAISES OUTLOOK · Record third quarter net revenue of $119 million, up 26% year-over-year · Record third quarter adjusted EBITDA of $25 million · Record third quarter net income of $18 million, up 362% year-over-year, and record third quarter adjusted net income of $20 million, up 53% year-over-year · Record nine-month net revenue of $523 million, up 27% year-over-year · Record nine-month adjusted EBITDA of $135 million · Record nine-month net op ...